September 7, 2016
The Japanese Medical and Dental Practitioners for the Improvement of Medical Care (Hodanren) said on September 6 that it has submitted a request calling for out-of-cycle re-pricing for Ono Pharmaceutical’s immuno-oncology drug Opdivo (nivolumab). In its request submitted to Health...read more